These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34213454)

  • 1. Metreleptin replacement treatment improves quality of life and psychological well-being in congenital generalized lipodystrophy.
    Simsir IY; Yurekli BS; Polat I; Saygili F; Akinci B
    Natl Med J India; 2020; 33(5):278-280. PubMed ID: 34213454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the
    Özalkak Ş; Demiral M; Ünal E; Taş FF; Onay H; Demirbilek H; Özbek MN
    J Clin Res Pediatr Endocrinol; 2023 Aug; 15(3):329-333. PubMed ID: 35735786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution.
    Adiyaman SC; V Schnurbein J; De Laffolie J; Hahn A; Siebert R; Wabitsch M; Kamrath C
    J Pediatr Endocrinol Metab; 2022 Jul; 35(7):946-952. PubMed ID: 35405042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
    Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.
    Christensen JD; Lungu AO; Cochran E; Collins MT; Gafni RI; Reynolds JC; Rother KI; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1493-500. PubMed ID: 25070319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG; Shukla AP; Aronne LJ
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T; Cochran E; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
    Fukaishi T; Minami I; Masuda S; Miyachi Y; Tsujimoto K; Izumiyama H; Hashimoto K; Yoshida M; Takahashi S; Kashimada K; Morio T; Kosaki K; Maezawa Y; Yokote K; Yoshimoto T; Yamada T
    Endocr J; 2020 Feb; 67(2):211-218. PubMed ID: 31708526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?
    Mantzoros CS
    Endocr Pract; 2010; 16(2):162-6. PubMed ID: 20350904
    [No Abstract]   [Full Text] [Related]  

  • 11. Congenital generalized lipodystrophies--new insights into metabolic dysfunction.
    Patni N; Garg A
    Nat Rev Endocrinol; 2015 Sep; 11(9):522-34. PubMed ID: 26239609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of disease characteristics of a large patient cohort with congenital generalized lipodystrophy from the Middle East and North Africa.
    Al Yaarubi S; Alsagheir A; Al Shidhani A; Alzelaye S; Alghazir N; Brema I; Alsaffar H; Al Dubayee M; Alshahrani A; Abdelmeguid Y; Omar OM; Attia N; Al Amiri E; Al Jubeh J; Algethami A; Alkhayyat H; Haleem A; Al Yahyaei M; Khochtali I; Babli S; Nugud A; Thalange N; Albalushi S; Hergli N; Deeb A; Alfadhel M
    Orphanet J Rare Dis; 2024 Mar; 19(1):118. PubMed ID: 38481246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy.
    Muniyappa R; Abel BS; Asthana A; Walter MF; Cochran EK; Remaley AT; Skarulis MC; Gorden P; Brown RJ
    J Clin Lipidol; 2017; 11(2):543-550. PubMed ID: 28502512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Options for Lipodystrophy in Children.
    Mainieri F; Tagi VM; Chiarelli F
    Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
    Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
    Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First metreleptin treatment for generalized lipodystrophy in Turkey.
    Simsir IY; Yurekli BS; Saygili F; Altay C; Akinci B
    Diabetes Obes Metab; 2017 Feb; 19(2):299-301. PubMed ID: 27717125
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
    Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
    Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
    J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metreleptin Treatment in Three Patients with Generalized Lipodystrophy.
    Musso C; Major ML; Andres E; Simha V
    Clin Med Insights Case Rep; 2016; 9():123-127. PubMed ID: 28096701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.